MX2020010301A - Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. - Google Patents
Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.Info
- Publication number
- MX2020010301A MX2020010301A MX2020010301A MX2020010301A MX2020010301A MX 2020010301 A MX2020010301 A MX 2020010301A MX 2020010301 A MX2020010301 A MX 2020010301A MX 2020010301 A MX2020010301 A MX 2020010301A MX 2020010301 A MX2020010301 A MX 2020010301A
- Authority
- MX
- Mexico
- Prior art keywords
- sequence
- fragment
- pharmaceutical compositions
- terminal
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
Abstract
La presente invención proporciona una secuencia de un fragmento de CDNF C-terminal, o una secuencia que tiene al menos 80 % de homología o identidad de secuencia con dicha secuencia. El fragmento CDNF C-terminal protege a las neuronas, neuronas motrices y neuronas dopaminérgicas con RE estresado, y el fragmento es capaz de penetrar la membrana celular neuronal y también la barrera hematoencefálica. La presente invención proporciona, además, dicho fragmento y composiciones farmacéuticas que comprenden dicho fragmento para usarse en el tratamiento de enfermedades y trastornos degenerativos que incluyen enfermedades del sistema nervioso central, diabetes y trastornos retinianos. La presente invención también proporciona una secuencia de un fragmento de MANF C-terminal, o una secuencia que tiene al menos 80 % de homología o identidad de secuencia con dicha secuencia, y composiciones farmacéuticas que comprenden dicho fragmento de MANF para usarse en el tratamiento de enfermedades y trastornos degenerativos que incluyen enfermedades del sistema nervioso central, diabetes y trastornos retinianos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20185304 | 2018-03-29 | ||
PCT/FI2019/050258 WO2019185994A1 (en) | 2018-03-29 | 2019-03-29 | C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010301A true MX2020010301A (es) | 2020-10-20 |
Family
ID=66103015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010301A MX2020010301A (es) | 2018-03-29 | 2019-03-29 | Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210009645A1 (es) |
EP (1) | EP3774858A1 (es) |
JP (2) | JP2021519578A (es) |
KR (1) | KR20200138798A (es) |
CN (1) | CN112616315A (es) |
AU (1) | AU2019244323A1 (es) |
BR (1) | BR112020019696A2 (es) |
CA (1) | CA3094236A1 (es) |
IL (1) | IL277632A (es) |
MX (1) | MX2020010301A (es) |
RU (1) | RU2020131433A (es) |
SG (1) | SG11202009341TA (es) |
TW (1) | TW202003015A (es) |
WO (1) | WO2019185994A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202202898D0 (en) * | 2022-03-02 | 2022-04-13 | Babraham Inst | Novel use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
JPH06501617A (ja) * | 1990-09-25 | 1994-02-24 | ジェネンテク,インコーポレイテッド | 新規な神経栄養因子 |
ATE485377T1 (de) * | 2001-03-20 | 2010-11-15 | Cns Protein Therapeutics Inc | Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen |
CA2576030A1 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
DE602005023550D1 (de) | 2005-12-14 | 2010-10-21 | Licentia Ltd | Verwendungen eines neurotrophischen Faktors |
FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
CN103987400B (zh) * | 2011-06-09 | 2019-09-13 | 迈阿密大学 | 治疗视网膜疾病的方法 |
FI20115870A0 (fi) * | 2011-09-05 | 2011-09-05 | Urmas Arumaee | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
WO2014191630A2 (en) | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
US20170157243A1 (en) * | 2014-06-24 | 2017-06-08 | University Of Massachusetts | MANF as a Regulator of Immune System Function |
US20170252403A1 (en) * | 2014-10-06 | 2017-09-07 | Amarantus Bioscience Holdings, Inc. | Methods and compositions for treating retinal disorders |
AU2018263087B2 (en) * | 2017-05-04 | 2021-12-16 | Helsingin Yliopisto | C-terminal CDNF and manf fragments, pharmaceutical compositions comprising same and uses thereof |
CN107149673A (zh) * | 2017-05-18 | 2017-09-12 | 山东大学 | 神经营养因子cdnf在制备缺血性脑血管疾病药物中的应用 |
-
2019
- 2019-03-29 TW TW108111334A patent/TW202003015A/zh unknown
- 2019-03-29 MX MX2020010301A patent/MX2020010301A/es unknown
- 2019-03-29 KR KR1020207031336A patent/KR20200138798A/ko unknown
- 2019-03-29 EP EP19717122.6A patent/EP3774858A1/en active Pending
- 2019-03-29 BR BR112020019696-7A patent/BR112020019696A2/pt not_active IP Right Cessation
- 2019-03-29 SG SG11202009341TA patent/SG11202009341TA/en unknown
- 2019-03-29 RU RU2020131433A patent/RU2020131433A/ru unknown
- 2019-03-29 CA CA3094236A patent/CA3094236A1/en active Pending
- 2019-03-29 CN CN201980036267.7A patent/CN112616315A/zh active Pending
- 2019-03-29 US US17/043,028 patent/US20210009645A1/en active Pending
- 2019-03-29 WO PCT/FI2019/050258 patent/WO2019185994A1/en active Application Filing
- 2019-03-29 AU AU2019244323A patent/AU2019244323A1/en not_active Abandoned
- 2019-03-29 JP JP2020552209A patent/JP2021519578A/ja active Pending
-
2020
- 2020-09-29 IL IL277632A patent/IL277632A/en unknown
-
2024
- 2024-02-02 JP JP2024014651A patent/JP2024056762A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3774858A1 (en) | 2021-02-17 |
KR20200138798A (ko) | 2020-12-10 |
BR112020019696A2 (pt) | 2021-01-05 |
US20210009645A1 (en) | 2021-01-14 |
IL277632A (en) | 2020-11-30 |
JP2021519578A (ja) | 2021-08-12 |
CA3094236A1 (en) | 2019-10-03 |
RU2020131433A (ru) | 2022-05-04 |
SG11202009341TA (en) | 2020-10-29 |
WO2019185994A1 (en) | 2019-10-03 |
JP2024056762A (ja) | 2024-04-23 |
CN112616315A (zh) | 2021-04-06 |
TW202003015A (zh) | 2020-01-16 |
AU2019244323A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013157A (es) | Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. | |
Da Silva et al. | IL-10 cytokine released from M2 macrophages is crucial for analgesic and anti-inflammatory effects of acupuncture in a model of inflammatory muscle pain | |
EP4001277A3 (en) | Bicyclic compounds for diagnosis and therapy | |
BR112019010646A2 (pt) | métodos de tratamento de condições inflamatórias | |
WO2017062456A3 (en) | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof | |
BR112022013843A2 (pt) | Método de diferenciação de células neurais e composições relacionadas e métodos de uso | |
WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
CR20200326A (es) | Derivados de 1,3,4, 5-tetrahidro-2h-pirido[4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tal como la enfermedad de alzheimer. | |
EP4327873A3 (en) | Tpp1 formulations and methods for treating cln2 disease | |
AU2014212471A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
MX2021000955A (es) | Terapia de incremento mitocondrial para enfermedades mitocondriales primarias. | |
MX2021000954A (es) | Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales. | |
Damasceno et al. | Frutalin reduces acute and neuropathic nociceptive behaviours in rodent models of orofacial pain | |
BR112017005416A2 (pt) | composição farmacológica de tratamento e prevenção de doenças neurológicas degenerativas contendo como ingrediente ativo extrato de mistura de casca da raiz de peônia da montanha, raiz de angelica dahurica e raiz de bupleurum ou fragmentos dos mesmos | |
MX2020010301A (es) | Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. | |
MX2021012608A (es) | Nuevas moleculas para terapia y diagnostico. | |
MX2021012579A (es) | Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos. | |
MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
WO2003103573A3 (en) | METHODS OF TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL DELIVERY OF A TROPHIC FACTOR | |
MX2021004531A (es) | Nuevos usos. | |
Chang et al. | The effect on serotonin and MDA levels in depressed patients with insomnia when far-infrared rays are applied to acupoints | |
Lee et al. | Recent trend and proposal for acupuncture clinical trial on atopic dermatitis | |
Bellavite et al. | Homeopathy and placebo | |
Karia et al. | Tiapride for the treatment of auditory hallucinations in schizophrenia |